The evolving role of plerixafor in hematopoietic progenitor cell mobilization.

Item

http://www.wikidata.org/entity/Q38077807

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The evolving role of plerixafor in hematopoietic progenitor cell mobilization.

@en

type

Item

label

The evolving role of plerixafor in hematopoietic progenitor cell mobilization.

@en

prefLabel

The evolving role of plerixafor in hematopoietic progenitor cell mobilization.

@en

P1476

The evolving role of plerixafor in hematopoietic progenitor cell mobilization.

@en

P2093

Dan T Vogl

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Una O'Doherty

http://www.w3.org/2001/XMLSchema#string

Yvette C Tanhehco

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies

Cytokines and hematopoietic stem cell mobilization

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

Significant mobilization of both conventional and regulatory T cells with AMD3100.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

P304

2314-2326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TRF.12102

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23362980

http://www.w3.org/2001/XMLSchema#string